Loading video...

Video Failed to Load

Go Home

🧬 What do HCPs need to know about current treatment options for advanced/recurrent #EndometrialCancer? An animated #MedEd video from Prof. Christian Marth 📺 Hear about 👉 A patient case study 👉 Latest treatment strategies 👉 A shift from traditional chemotherapy to personalised therapies driven by molecular profiling. This educational...

OBGynConnect's profile picture

OBSTETRICS & GYNECOLOGY CONNECT

2,368 subscribers

462,512 views • 1 year ago •via X (Twitter)

Health & WellnessEducation#EndometrialCancer#MedEd
LIVE

Anya Rossi• Live Now

Private livecam show

1 Comments

Ivana Božović's profile picture
Ivana Božović1 year ago

Great overview, dense and i informative, thanks

Related Videos

Advanced or recurrent endometrial cancer: Molecular classification & treatment decisions Medical experts Prof. Xavier Matias-Guiu G & Dr Jurjees Hasan explain the impact of molecular subtypes in treatment decisions in this video podcast 📺 Watch the video below Listen on all podcast platforms / get the transcript 👉 This programme has been sponsored by Eisai Europe Limited ("Eisai"). Eisai has had no input on the educational content of, or speakers involved in this Video Podcast.
11:28

Advanced or recurrent endometrial cancer: Molecular classification & treatment decisions Medical experts Prof. Xavier Matias-Guiu G & Dr Jurjees Hasan explain the impact of molecular subtypes in treatment decisions in this video podcast 📺 Watch the video below Listen on all podcast platforms / get the transcript 👉 This programme has been sponsored by Eisai Europe Limited ("Eisai"). Eisai has had no input on the educational content of, or speakers involved in this Video Podcast.

OBSTETRICS & GYNECOLOGY CONNECT powered by COR2ED

167,006 views • 1 year ago

LEVIATHAN publication snapshot >> Expert insights on 2nd line treatment selection post atezolizumab + bevacizumab for HCC 📺 from Prof. David Pinato (David James Pinato 🇺🇦) >> Programme endorsed by European Liver Patients' Association, Blue Faery, Global Liver Institute & ESDO This programme is supported by an independent educational grant from Eisai Europe Limited. Eisai Europe Limited has financially supported this activity and has had no influence on its creation or content.
4:29

LEVIATHAN publication snapshot >> Expert insights on 2nd line treatment selection post atezolizumab + bevacizumab for HCC 📺 from Prof. David Pinato (David James Pinato 🇺🇦) >> Programme endorsed by European Liver Patients' Association, Blue Faery, Global Liver Institute & ESDO This programme is supported by an independent educational grant from Eisai Europe Limited. Eisai Europe Limited has financially supported this activity and has had no influence on its creation or content.

HCC CONNECT powered by COR2ED

701,758 views • 5 months ago

Did you catch this video podcast on the testing and treatment of BRAF-mutated #CRC? Prof. Sebastian Stintzing and Dr Thomas Winder discuss important topics such as diagnostic testing strategies and the latest treatment options for affected patients 📹 Watch the video highlights below Access the full video or listen to the audio podcasts here: 📷 Endorsed by Digestive Cancers Europe #MedicalEducation #PrecisionOncology This educational programme is supported by an Independent Educational Grant from Pierre Fabre Laboratories and is intended for HCPs outside of the UK and ROI only.
4:49

Did you catch this video podcast on the testing and treatment of BRAF-mutated #CRC? Prof. Sebastian Stintzing and Dr Thomas Winder discuss important topics such as diagnostic testing strategies and the latest treatment options for affected patients 📹 Watch the video highlights below Access the full video or listen to the audio podcasts here: 📷 Endorsed by Digestive Cancers Europe #MedicalEducation #PrecisionOncology This educational programme is supported by an Independent Educational Grant from Pierre Fabre Laboratories and is intended for HCPs outside of the UK and ROI only.

GI CONNECT

309,461 views • 1 year ago

Personalised treatment in childhood cancer: A journey through 𝘕𝘛𝘙𝘒 fusion testing 📺Video for patients & families – please share with your network From Linet Menachery, patient advocate and mother of a child diagnosed with an 𝘕𝘛𝘙𝘒 fusion-positive pediatric cancer Endorsed by NTRKers, ICAN, International Cancer Advocacy Network & Biomarker Collaborative Supported by an Independent Educational Grant from Bayer
4:51

Personalised treatment in childhood cancer: A journey through 𝘕𝘛𝘙𝘒 fusion testing 📺Video for patients & families – please share with your network From Linet Menachery, patient advocate and mother of a child diagnosed with an 𝘕𝘛𝘙𝘒 fusion-positive pediatric cancer Endorsed by NTRKers, ICAN, International Cancer Advocacy Network & Biomarker Collaborative Supported by an Independent Educational Grant from Bayer

COR2ED

5,214,734 views • 3 months ago

HER2+ metastatic breast cancer How can we manage TRAEs e.g. N+V/fatigue/ILD? 📺 Video from Prof. Javier Cortes MD PhD Supported by an Independent Educational Grant from AstraZeneca
3:33

HER2+ metastatic breast cancer How can we manage TRAEs e.g. N+V/fatigue/ILD? 📺 Video from Prof. Javier Cortes MD PhD Supported by an Independent Educational Grant from AstraZeneca

BREAST CANCER CONNECT powered by COR2ED

5,825,134 views • 1 month ago

ER+/HER2- metastatic breast cancer: Highlights from APBCS 2026 Satellite Symposium, chaired by Dr Mastura Md Yusof 📺 Experts discuss 2L+ treatment strategies in endocrine therapy-eligible patients From Dr Hope S. Rugo (Hope Rugo) and Prof. Matteo Lambertini (Matteo Lambertini, MD PhD) This programme has been sponsored by Menarini Stemline and is intended for HCPs only. Brought to you by COR2ED Medical Affairs
4:58

ER+/HER2- metastatic breast cancer: Highlights from APBCS 2026 Satellite Symposium, chaired by Dr Mastura Md Yusof 📺 Experts discuss 2L+ treatment strategies in endocrine therapy-eligible patients From Dr Hope S. Rugo (Hope Rugo) and Prof. Matteo Lambertini (Matteo Lambertini, MD PhD) This programme has been sponsored by Menarini Stemline and is intended for HCPs only. Brought to you by COR2ED Medical Affairs

COR2ED

7,632,504 views • 4 months ago

GI CONNECT podcast episode Tackling metastatic pancreatic ductal adenocarcinoma (mPDAC) Dr. Shubham Pant & Prof. Efrat Dotan MD discuss chemotherapy strategies that matter Conversation topics include: - Efficacy & safety profiles - Relevance of mode of delivery - Cause of toxicities - Strategies to manage side effects 📹 Highlights video in this post Endorsed by ICAN, International Cancer Advocacy Network Digestive Cancers Europe The National Pancreas Foundation PanCAN Supported by an Independent Educational Grant from Ipsen USA
4:31

GI CONNECT podcast episode Tackling metastatic pancreatic ductal adenocarcinoma (mPDAC) Dr. Shubham Pant & Prof. Efrat Dotan MD discuss chemotherapy strategies that matter Conversation topics include: - Efficacy & safety profiles - Relevance of mode of delivery - Cause of toxicities - Strategies to manage side effects 📹 Highlights video in this post Endorsed by ICAN, International Cancer Advocacy Network Digestive Cancers Europe The National Pancreas Foundation PanCAN Supported by an Independent Educational Grant from Ipsen USA

GI CONNECT powered by COR2ED

1,202,819 views • 8 months ago

When should early treatment intensification w/ PARPi + ARPI combination be considered for mCRPC patients? 📺 Find out in this patient case video >> You’ll also discover the SHARE Communication Framework to use with your pts in clinical practice SHARE is made up of 5 key elements: S – Success criteria & aim of treatment H – How the treatments work A – Advantages/disadvantages of each Tx option R – Risks & effective management of side effects E – Expectations for Tx success Part 1 of the highlights video in this post ~ Endorsed by Urobel & ZERO Prostate Cancer Supported by an Independent Educational Grant from AstraZeneca
5:33

When should early treatment intensification w/ PARPi + ARPI combination be considered for mCRPC patients? 📺 Find out in this patient case video >> You’ll also discover the SHARE Communication Framework to use with your pts in clinical practice SHARE is made up of 5 key elements: S – Success criteria & aim of treatment H – How the treatments work A – Advantages/disadvantages of each Tx option R – Risks & effective management of side effects E – Expectations for Tx success Part 1 of the highlights video in this post ~ Endorsed by Urobel & ZERO Prostate Cancer Supported by an Independent Educational Grant from AstraZeneca

GU CONNECT powered by COR2ED

164,512 views • 5 months ago

Update from ESGO 2026 PYNNACLE Phase 2 study: Interim results from the ovarian cancer cohort Evaluating a first-in-class p53 reactivator, rezatapopt*, in TP53 Y220C–mutant advanced solid tumours 📺 Clinical insights and expert discussion from Profs Domenica Lorusso and Jean-Sebastien Frenel This programme has been sponsored by PMV Pharma and is intended for HCPs only. Brought to you by COR2ED Medical Affairs. *Rezatapopt is an investigational agent which is not approved by a regulatory agency
5:19

Update from ESGO 2026 PYNNACLE Phase 2 study: Interim results from the ovarian cancer cohort Evaluating a first-in-class p53 reactivator, rezatapopt*, in TP53 Y220C–mutant advanced solid tumours 📺 Clinical insights and expert discussion from Profs Domenica Lorusso and Jean-Sebastien Frenel This programme has been sponsored by PMV Pharma and is intended for HCPs only. Brought to you by COR2ED Medical Affairs. *Rezatapopt is an investigational agent which is not approved by a regulatory agency

COR2ED

5,788,485 views • 4 months ago

🇨🇳 Watch the final film from the Mandarin Excellence Programme intensive study visit to China! ✈️ More than 1000 students from 62 schools visited China in July for an educational tour to improve their Mandarin-speaking skills and cultural awareness. Find out more about the study visit:
3:01

🇨🇳 Watch the final film from the Mandarin Excellence Programme intensive study visit to China! ✈️ More than 1000 students from 62 schools visited China in July for an educational tour to improve their Mandarin-speaking skills and cultural awareness. Find out more about the study visit:

British Council Schools

198,098 views • 11 months ago

📢 New on-demand webinar! ➡️ #HER2 immunohistochemistry testing in #lungcancer & #ovariancancer w/ Profs. Fernando López-Ríos, Christian Rolfo & Charlie Gourley Watch the full webinar & download the experts’ slides 👇 Supported by an Independent Educational Grant from AstraZeneca #MedEd #PrecisionMedicine #PrecisionOncology #OncTwitter 📹
5:00

📢 New on-demand webinar! ➡️ #HER2 immunohistochemistry testing in #lungcancer & #ovariancancer w/ Profs. Fernando López-Ríos, Christian Rolfo & Charlie Gourley Watch the full webinar & download the experts’ slides 👇 Supported by an Independent Educational Grant from AstraZeneca #MedEd #PrecisionMedicine #PrecisionOncology #OncTwitter 📹

PRECISION ONCOLOGY CONNECT

247,079 views • 1 year ago

ADCs in HER2+ metastatic breast cancer: management of adverse events Get step-by-step strategies to support effective management of T-DXd–related adverse events in HER2+ mBC > N/V > Fatigue > Interstitial lung disease (rare but critical) From Prof. Shaheenah Dawood, Dr Sara Tolaney, Prof. Javier Cortes MD PhD, Carla Whitbread, Dr Grazyna Suchodolska & Prof. Giuseppe Curigliano Endorsed by the European Oncology Nursing Society (@cancernurseEU) and Europa Donna Supported by an Independent Educational Grant from AstraZeneca
3:41

ADCs in HER2+ metastatic breast cancer: management of adverse events Get step-by-step strategies to support effective management of T-DXd–related adverse events in HER2+ mBC > N/V > Fatigue > Interstitial lung disease (rare but critical) From Prof. Shaheenah Dawood, Dr Sara Tolaney, Prof. Javier Cortes MD PhD, Carla Whitbread, Dr Grazyna Suchodolska & Prof. Giuseppe Curigliano Endorsed by the European Oncology Nursing Society (@cancernurseEU) and Europa Donna Supported by an Independent Educational Grant from AstraZeneca

BREAST CANCER CONNECT powered by COR2ED

7,263,743 views • 4 months ago

Are ADCs the next therapeutic options for pts w/ pretreated HR+/HER2- (IHC 0) metastatic breast cancer who have developed an endocrine resistance? Find out as you follow a pt journey in this case-based video Endorsed by ICAN, International Cancer Advocacy Network Biomarker Collaborative GRASP & Exon 20 Group, a multistakeholder organization Supported by an Independent Educational Grant from AstraZeneca.
9:15

Are ADCs the next therapeutic options for pts w/ pretreated HR+/HER2- (IHC 0) metastatic breast cancer who have developed an endocrine resistance? Find out as you follow a pt journey in this case-based video Endorsed by ICAN, International Cancer Advocacy Network Biomarker Collaborative GRASP & Exon 20 Group, a multistakeholder organization Supported by an Independent Educational Grant from AstraZeneca.

BREAST CANCER CONNECT

1,019,784 views • 9 months ago

📺 Cem Karsan 🥐 covers the basics of options Greeks Access educational resources about options trading from The Options Institute:
2:04

📺 Cem Karsan 🥐 covers the basics of options Greeks Access educational resources about options trading from The Options Institute:

Cboe

44,213 views • 1 year ago

🧬Precision oncology in HR+/HER2- metastatic #breastcancer. Dr Callahan and Dr Salgado discuss: Essential #biomarkers (ESR1m, PIK3CA, gBRCA) and their clinical implications, Liquid vs tumour biopsy – when and how? Single gene vs broad panel testing…and much more! 📹 Watch the video highlights in this post 🗣️Get the full conversation/listen to the audio on Spotify/Apple: Supported by an Independent Educational Grant from Thermo Fisher Scientific #MedEd #BCSM #OncTwitter
5:51

🧬Precision oncology in HR+/HER2- metastatic #breastcancer. Dr Callahan and Dr Salgado discuss: Essential #biomarkers (ESR1m, PIK3CA, gBRCA) and their clinical implications, Liquid vs tumour biopsy – when and how? Single gene vs broad panel testing…and much more! 📹 Watch the video highlights in this post 🗣️Get the full conversation/listen to the audio on Spotify/Apple: Supported by an Independent Educational Grant from Thermo Fisher Scientific #MedEd #BCSM #OncTwitter

BREAST CANCER CONNECT

112,471 views • 1 year ago

All African countries need to learn from China, by regulating our educational system to create entrepreneurs from an early age rather than creating a workforce or jobless population.
0:31

All African countries need to learn from China, by regulating our educational system to create entrepreneurs from an early age rather than creating a workforce or jobless population.

Typical African

124,643 views • 1 year ago

Navigating extrapulmonary neuroendocrine carcinoma (EP-NEC) >> This is a rare and complex cancer that needs early diagnosis and intervention 📺 Watch the video from Meredith Cummins, INCA President-Elect, and CEO of NeuroEndocrine Cancer Australia, to find out: -Why urgency is needed in diagnosis & treatment -The potential of investigational treatments -Where to find support Endorsed by: INCA (NET Cancer Day). NeuroEndocrine Cancer Australia, Neuroendocrine Cancer UK #NotJustNECancer, Neuroendocrine Cancer Foundation, Neuroendocrine Cancer Research Foundation & Minkahz NETs Mission Supported by an Independent Educational Grant from Boehringer Ingelheim
5:45

Navigating extrapulmonary neuroendocrine carcinoma (EP-NEC) >> This is a rare and complex cancer that needs early diagnosis and intervention 📺 Watch the video from Meredith Cummins, INCA President-Elect, and CEO of NeuroEndocrine Cancer Australia, to find out: -Why urgency is needed in diagnosis & treatment -The potential of investigational treatments -Where to find support Endorsed by: INCA (NET Cancer Day). NeuroEndocrine Cancer Australia, Neuroendocrine Cancer UK #NotJustNECancer, Neuroendocrine Cancer Foundation, Neuroendocrine Cancer Research Foundation & Minkahz NETs Mission Supported by an Independent Educational Grant from Boehringer Ingelheim

COR2ED

757,945 views • 5 months ago

Started publishing educational videos about This is the first video in that series... ...showing an overview of what SiteGPT is. Uploading a very long video on Twitter for the first time 😅
7:10

Started publishing educational videos about This is the first video in that series... ...showing an overview of what SiteGPT is. Uploading a very long video on Twitter for the first time 😅

Bhanu Teja P

23,576 views • 2 years ago